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Antimicrobial peptides (AMPs) are part of the innate immune defense mechanism of many
organisms. Although AMPs have been essentially studied and developed as potential
alternatives for fighting infectious diseases, their use as anticancer peptides (ACPs) in
cancer therapy either alone or in combination with other conventional drugs has been
regarded as a therapeutic strategy to explore. As human cancer remains a cause of high
morbidity and mortality worldwide, an urgent need of new, selective, and more efficient
drugs is evident. Even though ACPs are expected to be selective toward tumor cells
without impairing the normal body physiological functions, the development of a selective
ACP has been a challenge. It is not yet possible to predict antitumor activity based on ACPs
structures. ACPs are unique molecules when compared to the actual chemotherapeutic
arsenal available for cancer treatment and display a variety of modes of action which in
some types of cancer seem to co-exist. Regardless the debate surrounding the definition
of structure-activity relationships for ACPs, great effort has been invested in ACP design
and the challenge of improving effective killing of tumor cells remains. As detailed studies
on ACPs mechanisms of action are crucial for optimizing drug development, in this
review we provide an overview of the literature concerning peptides’ structure, modes
of action, selectivity, and efficacy and also summarize some of the many ACPs studied
and/or developed for targeting different solid and hematologic malignancies with special
emphasis on the first group. Strategies described for drug development and for increasing
peptide selectivity toward specific cells while reducing toxicity are also discussed.
Keywords: anticancer peptides, tumor selectivity, electrostatic interactions, membrane disruption, apoptosis
induction, necrosis, drug development
INTRODUCTION: LEADING ANTIMICROBIAL PEPTIDES INTO
ANTICANCER THERAPY
Inappropriate and irrational use of antibiotics has induced the
worldwide emergence and spreading of resistant microorgan-
isms. Nowadays, understanding the biological and biomedical
importance of antimicrobial peptides might be regarded as an
advance toward new and resistance-free therapies for infec-
tious diseases. Antimicrobial peptides constitute a mechanism
of immune defense with low antigenicity (Iwasaki et al., 2009)
that can be found in innumerous eukaryotic organisms of dif-
ferent species (Reddy et al., 2004). These are small and gener-
ally amphipathic molecules, most of them containing cationic
and hydrophobic residues in elevated proportion, thus capable
of interacting with microbial membranes (Brandenburg et al.,
2012; Seo et al., 2012) through non-specific interactions with the
membrane lipids (Arouri et al., 2009). The short time-frame of
interaction promotes the microbe rapid death and decreases the
probability of resistance development (Fernebro, 2011). There is
immense structural diversity in the several hundred AMPs that
have been studied until today (Maroti et al., 2011). There are
α-helical (such as cecropins), cysteine-rich and β-sheet AMPs
(such as defensins). It is also common to find AMPs rich in His,
Arg, Pro, and Trp (like indolicidin for instance) (Reddy et al.,
2004).
Although Gram-positive and Gram-negative bacteria are the
most studied targets for AMPs, many other different targets have
been described, like fungi, protozoa (Giuliani et al., 2007) and
enveloped viruses, such as HIV and herpes virus (Hancock and
Diamond, 2000). The scientific literature is also rich in studies
providing information on the mechanisms of action of AMPs
(Friedrich et al., 2000; Mika et al., 2011). It is well established
that the ability of these small cationic molecules in disrupting
and permeating cell membranes is dependent on several biophys-
ical properties, such as peptides’ secondary structure, overall net
charge, amphipathicity, hydrophobicity, size and balance between
hydrophobic and polar regions (Reddy et al., 2004; Teixeira
et al., 2012). This ability in permeating the cellular membrane
is correlated with the antibiotic effect of several AMPs, such as
defensins and cecropins (Steiner et al., 1988; Cociancich et al.,
1993). Membrane disruption by AMPs can occur through dif-
ferent modes. It can either consist in pore formation in the lipid
membrane (barrel stave and toroidal pore models), thinning of
the membrane bilayer, membrane dissolution (carpet model), or
lipid-peptide domain formation. In other cases AMPs are capa-
ble of intracellular targeting of the pathogen (Yeaman and Yount,
2003; Brogden, 2005; Papo and Shai, 2005; Bechinger and Lohner,
2006; Chan et al., 2006) since AMPs can bind to nucleic acids
and proteins (Hancock and Sahl, 2006). There are also reports
describing immunomodulatory activities for AMPs (Jerala and
Porro, 2004; McPhee et al., 2005) such as the stimulation of
chemokine and cytokines production as well as chemotaxis for
leukocytes (Bowdish et al., 2005). For further detail on AMPs
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structures, mechanisms and potential pharmaceutical applica-
tions, the reader is referred to the reviews by Li et al. and Brogden
et al. (Brogden, 2005; Li et al., 2012). In addition to these well-
known and described activities and targets, a growing number of
studies report a broad spectrum of cytotoxic activity against can-
cer cells by these peptides (Moore et al., 1994; Mader and Hoskin,
2006; Hoskin and Ramamoorthy, 2008; Berge et al., 2010).
Cancer remains a major cause of death affecting millions of
people and is caused by the growth and spreading of abnormal
cells in an uncontrolled manner. Estimates from the international
Agency for Research on Cancer (IARC) indicate that 12.7 mil-
lion of new cancer cases and 7.6 million cancer deaths occurred
worldwide during 2008 (Ferlay et al., 2010). Also, the worldwide
statistics reveal that the most commonly diagnosed cancers are
lung, breast and colorectal (Parkin et al., 2005; Ferlay et al., 2010).
In the last decades many effort has been devoted in creating new
therapies that are at the same time more selective and less harm-
ful for the patients. Despite this, the methods today available such
as surgery and chemotherapy have a relatively low success rate as
well as they present a risk of reoccurrence (Harris et al., 2011).
Indeed, chemotherapy treatment of prostate, bladder, kidney and
pancreatic cancer as well as metastatic melanoma is being inef-
ficient (Riedl et al., 2011a). For these cases where reoccurrence
and/or metastasis occur, chemotherapy is the first line of defense
(Riedl et al., 2011b). The therapeutic arsenal includes natural
products, DNA-alkylating agents, hormone agonists/antagonists
and antimetabolites but all of them presenting an insufficient
selectivity and consequently an unspecific targeting of healthy
mammalian cells with many deleterious effects (Kalyanaraman
et al., 2002; Al-Benna et al., 2011). In fact, as chemical agents
that are designed to attack the rapidly cancer dividing cells, they
are expected to induce side-effects on normal cells that divide at
the same rate. Consequently, it is very frequent the occurrence of
myelossupression and thrombocytopenia (decreased production
of blood cells), mucositis (inflammatory event on the digestive
tract) and alopecia (hair loss) due to the non-selective targeting
of cells from bone marrow, gastrointestinal tract and hair follicles
(Riedl et al., 2011b). Moreover, once many of these compounds
pass through the cell membrane and enter the cytosol they are
transported back to the outside of the cell as a part of a mecha-
nism of resistance from the cancerous cells (Perez-Tomas, 2006).
Besides the increase of the drug transporters that carry the anti-
cancer agent out of the cell, other mechanisms of multiple drug
resistance (MDR) may be described. These include the ability of
the cell to repair suffered DNA damage, tolerance to stress con-
ditions and abnormal expression of drug detoxifying enzymes
(Gatti and Zunino, 2005).
In a time where the number of people suffering from a
cancer-related disease increases each day and where conventional
therapies gather a worrying number of deficits and drawbacks,
new treatment options are a demand for symptoms relieving and
ultimately the eradication of the disease. In this context, anti-
cancer peptides have been proved to be a resourceful strategy for
the molecularly targeted cancer drug discovery and development
process. Small molecules with an efficient tissue penetration and
uptake by the heterogeneous cancer cells, endowed with intrin-
sic activity or synergizing with existing therapeutics, are expected
to result in improved anticancer drugs with higher selectivity for
neoplastic cells and reduced harmful effects over healthy tissues.
ANTICANCER PEPTIDES—CLASSIFICATION, SELECTIVITY,
AND MODES OF ACTION
In a structural point of view, most ACPs have either α-helical or
β-sheet conformation but some extended structures have already
been reported (Hoskin and Ramamoorthy, 2008; Rodrigues et al.,
2009; Wang et al., 2009a; Hammami and Fliss, 2010). Concerning
cell targets, they can be classified into two major groups. The first
one includes peptides active against microbial and cancer cells
while not being active against healthy mammalian cells, such as
cecropins and magainins. The second group contains ACPs that
act against all three types of cells: microbial, normal and can-
cerous (Papo and Shai, 2005; Hoskin and Ramamoorthy, 2008),
such as human neutrophil defensins HNP-1 to 3 (Papo and Shai,
2005; Droin et al., 2009). For a complete list of ACPs the reader
is referred to the database available on http://aps.unmc.edu/AP/
database/antiC.php.
Themechanism and selectivity criteria by which ACPs kill can-
cerous cells is still a controversial theme although some major
conclusions can be outlined. ACPs oncolytic effects may generally
occur either by membranolytic or non-membranolytic mech-
anisms (Harris et al., 2013). The mechanism underlying each
membranolytic peptide activity is dependent on the ACP charac-
teristics as well as on the target membrane features, which in turn
modulate peptides’ selectivity and toxicity (Schweizer, 2009). In
fact, cancer and normal mammalian cells have a number of differ-
ences that are accounted responsible for the selectivity of some of
the ACPs. These differences rely firstly in the membrane net neg-
ative charge that characterizes malignant cells (Schweizer, 2009).
Anionic molecules such as the phospholipid phosphatidylserine
(PS), O-glycosylated mucins, sialylated gangliosides and heparin
sulfate are present in the membrane of cancer cells, conferring
them a net negative charge which contrasts with the normalmam-
malian cell membrane, typically zwitterionic in nature (Hoskin
and Ramamoorthy, 2008; Schweizer, 2009). Increased sialic acid
content on the membrane affects membrane charge by stimu-
lating surface concentration of acid groups (Dobrzynska et al.,
2005). In addition to the modified glycosilation profile typical
of cancer tissues and which is directly associated with the tumor
phenotype (Dube and Bertozzi, 2005), during cell transforma-
tion PSmolecules will present themselves on the outer membrane
leaflet, accumulating on site and counteracting the typical phos-
pholipid asymmetry of themembrane (Utsugi et al., 1991; Hoskin
and Ramamoorthy, 2008; Schweizer, 2009). Along with the zwit-
terionic lipids, normal cell membranes have high contents of
cholesterol which has been proposed as a protective molecule
of the membrane by modulating the cell fluidity and blocking
the entry/passage of cationic peptides (Schweizer, 2009). On the
opposite, most cancer cell membranes are described to be more
fluid than normal cells (Kozlowska et al., 1999; Sok et al., 1999)
allowing membrane destabilization by ACPs. Nevertheless, there
has been also shown that certain tumors, like breast and prostate,
present a higher content of cholesterol in the cell membranes (Li
et al., 2006) posing an obstacle to the lysis by ACPs. The cell
surface area is also a factor controlling ACPs activity since the
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elevated number and distorted features ofmicrovili present on the
malignant cells confer them higher surface area and higher con-
tact with ACPs molecules (Domagala and Koss, 1980; Chaudhary
and Munshi, 1995; Chan et al., 1998).
The negative surface charge of the cancer cell membrane is
a characteristic also shared by the bacterial cells (Mader and
Hoskin, 2006; Hoskin and Ramamoorthy, 2008). This fact lead
to the hypothesis that AMPs and ACPs share similar molecular
principles for selectivity and activity (van Zoggel et al., 2012).
However, not all AMPs are ACPs (Hoskin and Ramamoorthy,
2008) and so it is of crucial importance the comprehension of
all factors that allow ACPs to recognize and lyse neoplastic cells
for understanding efficacy and selectivity phenomena. Unraveling
the specific targets that are expressed and presented within a cer-
tain tumor type will be a valuable source of information in the
process of drug design.
ACPs’ membranolytic and selective mode of action on tumor
cells can be due to the increased anionicity of the cytoplasmic
membrane of these cells. The same “carpet” and “barrel-stave”
models, for instance, used for describing AMPs interaction with
bacterial membranes are also applied in this case (Pouny and Shai,
1992; Oren and Shai, 1998; Schweizer, 2009). Further membra-
nolytic events involve the permeation and swelling of mitochon-
dria with release of cytochrome c and apoptosis events (Mai et al.,
2001). Although the rapid killing associated to ACPs might imply
the prevalence of a non-receptor mediated mode of action, some
non-membranolytic activities for ACPs have also been described
(Sharma, 1992; Wachinger et al., 1998; Winder et al., 1998).
Different attempts in controlling tumorigenesis involve the tar-
geting of the angiogenesis process. Peptides that block the func-
tion of receptors expressed on angiogenic endothelial cells and
that by this way perturb the formation of the vasculature associ-
ated to a tumor have been described (Arap et al., 1998; Mader and
Hoskin, 2006; Schweizer, 2009; Lee et al., 2011; Rosca et al., 2011).
The main goal nowadays when using an anti-angiogenic therapy
is to normalize the tumor vasculature instead of reducing the den-
sity of tumor blood vessels (Shang et al., 2012). The development
of therapeutic molecules which by their own or in a combina-
tion with other chemotherapy agents target several aspects of the
angiogenic events might prove fruitful in cancer treatment (Rosca
et al., 2011).
ANTICANCER PEPTIDES FOR SOLID AND HEMATOLOGICAL
TUMORS
Regardless the many scientific studies published in which pep-
tides are shown to successfully eliminate tumor cells both in vitro
and in vivo and also prevent metastases formation (Cruciani et al.,
1991; Ellerby et al., 2003; Papo et al., 2003, 2004, 2006), there has
always been difficulties in establishing a clear structure-activity
relationship for ACPs that might facilitate drug development.
Targeted peptides which recognize tumors and metastases in a
specific manner are difficult to obtain. In this section, informa-
tion concerning ACPs that have been designed, synthesized or
isolated and studied for targeting specific tumor cells is provided.
Due to the vast broad spectrum of cancer cells tested for each
ACP in study, the different tumors have been divided into two
main groups, hematological and solid, and some of the ACPs that
have been described to target cells from each group are reviewed
with special emphasis on the solid tumors. Selectivity, efficacy and
major requirements for anticancer activity are discussed. As the
literature is vast concerning this matter, this review is focused in
a period covering nearly 20 years of AMP cancer cell treatment.
Table 1 shows the primary sequence of some of the peptides with
anticancer activity described in this review.
SOLID TUMORS
Solid tumors are characterized by a mass of tissue without cysts or
liquid areas. In these tumors it is possible to distinguishmalignant
cells and the stroma where these cells are maintained (Dvorak
et al., 1986). The tumor masses are represented by phenotypi-
cally heterogeneous populations of cancer cells, each having its
own ability in proliferating and forming a new tumor (Reya et al.,
2001; Al-Hajj and Clarke, 2004). The physiology and morphol-
ogy of these tumors is largely deviated from the normal tissues
(Brown and Giaccia, 1998) and these differences are currently
being explored for selective cancer treatments in an attempt of
circumvent the low specificity of the actual chemical and radi-
ation therapy. Regarding the use of peptides in cancer therapy,
many ACPs have been developed for targeting different types
of solid tumors. Conclusions about structure requirements for
the selective targeting of this type of tumors remain elusive.
Available results show that ACPs target solid tumors by a variety
of mechanisms.
Breast and prostate cancers are the most frequently diagnosed
cancer in women and men aside from skin cancer (Jemal et al.,
2006; Gross and Andra, 2012). Estimates indicate that breast and
prostate cancers accounted for 23 and 14% of the total new cancer
cases only in 2008 (Ferlay et al., 2010). Moreover, prostate cancer
does not respond adequately to single or multiple drug regimens
(Papo et al., 2004). Breast, prostate, uterine cervix, liver and lung
are some of the targeted tumors for the development of ACPs.
Some of these peptides defy the malignant cells by apoptotic or
necrotic mechanisms after damaging cellular membranes, others
by intracellular targets and it is also possible that one single pep-
tide presents more than one mode of anticancer activity. Table 2
summarizes some of the ACPs studied in the targeting of solid
tumors.
Electrostatic interactions are key activity modulators
In a pioneer study, Iwasaki et al. evaluated by flow cytometry
the PS density on the surface of several cancer cell lines and
established a correlation with cell sensitivity to AMPs using four
enantiomeric AMP analogs derived from beetle defensins (D-
peptides A, B, C, and D) (Iwasaki et al., 2009). The results showed
a selective cytotoxic activity dependent on the negative charge of
the cancer cell membrane and PS, providing direct proof of PS
role in the anticancer activity (Iwasaki et al., 2009). Papo et al. had
also reported on a short host defense-like peptide that inhibits the
growth of primary human prostate and breast carcinomas after
being injected intratumorally (Papo et al., 2004, 2006). The D-
K6L9 peptide induced a two-step cytolytic effect via membrane
disruption and necrosis of tumor cells alongside with a decrease
in the tumor vessel density, formation of new capillary tubes and
in the secretion of prostate-specific antigen secretion. It was also
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Table 1 | Peptides with anticancer activity toward solid and hematological tumors.
Peptide name Amino acid sequence References
D-peptide A
D-peptide B
D-peptide C
D-peptide D
RLYLRIGRR
RLRLRIGRR
ALYLAIRRR
RLLLRIGRR
Iwasaki et al., 2009
D-K6L9 LKLLKKLLKKLLKLL Papo et al., 2006
NRC-03
NRC-07
GRRKRKWLRRIGKGVKIIGGAALDHL
RWGKWFKKATHVGKHVGKAALTAYL
Hilchie et al., 2011
Gomesin ZCRRLCYKQRCVTYCRGR Rodrigues et al., 2008
Hepcidin TH2-3 QSHLSLCRWCCNCCRSNKGC Chen et al., 2009
Dermaseptin B2 GLWSKIKEVGKEAAKAAAKAAGKAALGAVSEAV van Zoggel et al., 2012
PTP7 FLGALFKALSKLL Kim et al., 2003
MGA2 GIGKFLHSAKKFGKAFVGEIMNSGGKKWKMRRNQF–WVKVQRG Liu et al., 2013
HNP-1 ACYCRIPACIAGERRYGTCIYQGRLWAFCC Wang et al., 2009c
Tachyplesin KWCFRVCYRGICYRRCR Chen et al., 2005
Temporin-1CEa FVDLKKIANIINSIF Wang et al., 2012
NK-2 KILRGVCKKIMRTFLRRISKDILTGKK Schroder-Borm et al., 2005
Bovine lactoferricin B6 (Lbcin B6) RRWQWR Richardson et al., 2009
Cecropin CB1 KWKVFKKIEKMGRNIRNGIVKAGPKWKVFKKIEK Srisailam et al., 2000
observed a decrease in the spontaneous and experimental metas-
tases formation (Papo et al., 2006). PS was identified as the target
for this peptide which colocalizes with the negatively charged
phospholipid and exerts a membrane-depolarizing lytic activity
on the neoplastic cells interacting with them in a selective way
(Papo et al., 2006). Further than PS molecules, many other mem-
brane components which contribute to the negative membrane of
the malignant cell have been selected as anticancer activity trig-
gers. Binding to negatively charged gangliosides expressed on the
cell surface can be a potential alternative for directing ACPs activ-
ity and a source of information to elucidate the mechanisms by
which AMPs bind to normal and cancerous cells (Hanai et al.,
2000; Bitton et al., 2002; Guo and Wang, 2009; Miyazaki et al.,
2012). NRC-03 and NRC-07 are two peptides from the AMP
pleurocidin family with activity against human breast cancer
cells including drug-resistant variants and with decreased affinity
toward human healthy cells even by intratumoral administration
(Hilchie et al., 2011). Peptides are able to bind the cancer cells and
cause membrane effects through negatively-charged molecules
that are exposed on the cells’ membrane, specifically heparan
and chondroitin sulfate. Cell death also involved mitochondrial
damage and reactive oxygen species (ROS) production (Hilchie
et al., 2011). Many other peptides were described, such as MPI-
1 (Zhang et al., 2010), Gomesin (Rodrigues et al., 2008), tilapia
hepcidin TH2-3 (Chen et al., 2009) and SVS-1 (Gaspar et al.,
2012; Sinthuvanich et al., 2012), that seem to target cancer cells
on the basis of charge rather than cell growth. MPI-1 is an ana-
log of the AMP polybia-MPI, a peptide isolated from the venom
of the wasp Polybia paulista (Wang et al., 2009b). MPI-1 peptide
has a thioamide bond substitution that selectively binds to human
prostate and liver cancer cells causing injury, swelling, bursting,
and final cell death by necrosis (Zhang et al., 2010). Scanning
electron microscopy (SEM) studies show the disruption of the
cell membrane and the authors point the peptide amphipatic
α-helical structure as crucial for its activity as well as the surface
charge of the cell (Zhang et al., 2010). It is also shown that the
thioamide bond substitution can be a valid strategy for design-
ing ACPs representing a conservative modification of the peptide
backbone structure (Zhang et al., 2010). The same authors have
previously demonstrated that the original peptide, polybia-MPI
selectively inhibited the proliferation of prostate and bladder can-
cer cells with low cytotoxicity for normal murine fibroblasts and
that the α-helical conformation was an important feature for
achieving an anticancer effect (Wang et al., 2008). The exposure
of PS on the cells’ membranes was suggested as a possible trigger
for the peptides selective killing ability (Wang et al., 2008).
Gomesin is a cationic AMP with a hairpin-like two-
stranded antiparallel β-sheet structure isolated from hemocytes
of Acanthoscurria gomesiana (Rodrigues et al., 2008). Rodrigues
et al. showed that this AMP possesses anticancer activity in vivo
after topical treatment for subcutaneous murine melanoma and
in vitro for melanoma, breast and colon carcinomas (Rodrigues
et al., 2008). Although the precise mode of action is not described
and may include pore formation, the cytotoxic activity was
dependent on the β-hairpin structure and electrostatic forces as
well as hydrophobic interactions which were already proved to
be important factors for the AMP activity (Fazio et al., 2007).
Most of the AMPs active against tumor cells adopt either a bioac-
tive helical conformation at the cell surface or a β-sheet structure
prior to engaging the membrane. SVS-1 peptide, a small designed
anticancer peptide, folds only at the surface of cancer cells and
acquires a β-sheet structure that disrupts the cell membrane via
pore formation (Figure 1) (Sinthuvanich et al., 2012). The pub-
lished studies show that this small 18-residue ACP folding is
electrostatically induced and cell death occurs before the peptide
neutralizes the cells’ negative membrane charge (Gaspar et al.,
2012). SVS-1 showed cytotoxic activity against lung, epidermal
and breast carcinoma cells and low toxicity against healthy cells
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Table 2 | Peptides and their respective oncolytic properties against solid tumors.
Peptide Cancer cell Experimental
test
Selectivity Anticancer activity References
D-peptides A, B, C and D Human cervix, glioma, lung,
mouse myeloma, african green
monkey kidney
ICL Yes Cell membrane
disruption
Iwasaki et al.,
2009
D-K6L9 Human prostate ICL/GEM Yes Necrosis via
membrane
depolarization
Papo et al., 2006
NRC-03, NRC-07 Human breast ICL/GEM No Cell membrane lysis
with possible pore
formation in
mitochondria and ROS
production
Hilchie et al.,
2011
MPI-1 Human cervix, prostate and
hepatocellular adenocarcinoma,
GEM Yes Necrosis after cell
membrane targeting
Zhang et al.,
2010
Polybia-MPI Human bladder and prostate ICL Yes Cell membrane
disruption with
probable pore
formation
Wang et al.,
2008
Gomesin Murine melanoma, human breast,
colon and cervix adenocarcinoma
ICL Nd Unclear; possible pore
formation
Rodrigues et al.,
2008
Hepcidin TH2-3 Human cervix, hepatocellular
carcinoma, fibrosarcoma
ICL Yes Cell membrane lysis Chen et al., 2009
SVS-1 Human lung, epidermis and
breast
ICL Yes Cell membrane
disruption via pore
formation
Gaspar et al.,
2012;
Sinthuvanich
et al., 2012
Epinecidin-1 Human lung, cervix,
hepatocellular carcinoma,
fibrosarcoma, histiocytic
lymphoma
ICL Yes Cell membrane lysis
mediated by necrosis
inhibitory activity
Lin et al., 2009
Dermaseptin B2 Human prostate and breast ICL/GEM Yes Necrosis van Zoggel et al.,
2012
PTP7 Human lung, prostate, breast and
hepatocellular carcinoma
ICL Yes Apoptosis induction Kim et al., 2003
BEPT II and BEPT II-1 Human prostate ICL Nd Apoptosis induction Ma et al., 2013
TfR-lytic peptide Human breast and prostate,
gliobastoma, pancreas and
bile-duct
ICL/GEM Yes Apoptosis induction Kawamoto et al.,
2011
BPC96 Human cervix ICL Yes Apoptosis induction Feliu et al., 2010
RGD-Tachyplesin Human prostate, melanoma ICL/GEM Some
selectivity
Apoptosis induction Chen et al., 2001
MG2A Human cervix and lung,
melanoma, rat glioma
ICL/GEM Yes Both necrosis and
apoptosis
Liu et al., 2013
A9K Human cervix, kidney ICL Yes Both necrosis and
apoptosis
Xu et al., 2013
(Continued)
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Table 2 | Continued
Peptide Cancer cell Experimental
test
Selectivity Anticancer activity References
HNP-1 Mouse colon and breast GEM Nd Mediation of antitumor
immunity
Wang et al.,
2009c
Hecate, Phor14 and Phor21 -BCG Human prostate, breast, ovarian
and testicular cells
ICL/GEM Yes Necrosis Leuschner et al.,
2003; Leuschner
and Hansel,
2005; Hansel
et al., 2007
Myristoyl-Cys-Ala-Val-Ala-Tyr-(1,3
dimethyl)His-OMe
Several human cell lines (lung,
colon, breast, ovarian, renal, . . . )
ICL Nd DNA
synthesis/replication
inhibition
Ourth, 2011
9 somatostatin peptide
analogues
Human colon ICL Yes DNA polymerase β
nhibition
Kuriyama et al.,
2013
Pentastatin-1, chemokinostatin-1,
properdistatin
Human breast ICL/GEM Nd Tumor growth and
angiogenesis inhibition
Koskimaki et al.,
2009
ERα17p Human breast ICL/GEM Nd Apoptosis induction
and massive necrosis
Pelekanou et al.,
2011; Byrne et al.,
2012
A-8R Human prostate ICL/GEM ROS generation and
DNA damage
Gao et al., 2013
CR1166 Human breast and pancreas ICL Yes Apoptosis induction Patra et al., 2012
Peptide aptamers Human cervix, mouse melanoma,
rat colon
ICL/GEM Nd Apoptosis induction by
inhibition of HSP-70
Rerole et al., 2011
Tachyplesin Human prostate ICL Nd Activation of the classic
complement pathway
Chen et al., 2005
Temporin-1CEa Human breast ICL Yes Membrane disruption,
calcium release, ROS
production
Wang et al., 2012,
2013a,b
Nd, not determined; ICL, immortal cancer-cell lineage; GEM, grafts experimental model (xenografts).
(HUVEC and erythrocytes) (Gaspar et al., 2012; Sinthuvanich
et al., 2012). Recent studies point to a neutralization of the bacte-
rial membrane charge that coincides or is closely related to min-
imal inhibitory concentration (MIC) values (Alves et al., 2010)
contrary to what might happen with ACPs (Figure 2). Therefore,
SVS-1 studies together with others which have been conducted
with different types of peptides (Kim et al., 2003) clearly show that
antitumor cell activities may actually not parallel AMPs mode of
action and that differences should be expected. Furthermore, the
different expression patterns of negatively charged molecules on
cancer cell membranes will be a limiting factor conditioning the
binding and engagement of peptides in the membrane and conse-
quently dictating the ability of each peptide in killing specific cells.
This points to the possibility of the same peptide to act by differ-
ent mechanisms depending on the cell type in question (Yoo et al.,
1997; Eliassen et al., 2006) and to be selective against determined
types of cancer.
Interfering with necrosis and apoptosis mechanisms
After engagement of ACPs in the cell membrane, the peptides may
penetrate into intracellular spaces. This entrancemight lead to the
disruption of the cell membrane accompanied by pore formation
and/or changes on the cell membrane charge (Janek et al., 2013)
and finally the interference with necrotic (Maher and McClean,
2008; Huang et al., 2011; Ausbacher et al., 2012; Wang et al.,
2013a) and apoptotic pathways (Ausbacher et al., 2012). Pore for-
mation is a mechanism associated to some AMPs and has been
reported for ACPs as well (Rodrigues et al., 2009). The insertion of
bulky hydrophobic amino acids on the cell membrane hydropho-
bic core with the acquisition of a stable structure can be the
driving events for pore formation (Hilchie et al., 2011). Cell death
might be a result of apoptosis and/or necrosis, which are char-
acterized by different cellular morphological changes (Elmore,
2007). Indeed, apoptosis of cancer cells is a recognized strategy
in cancer therapy (Qiao and Wong, 2009). While analyzing the
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FIGURE 1 | SVS-1 anticancer peptide disrupts the cell membrane after
engaging the membrane surface and folding into a β-hairpin
conformation (Sinthuvanich et al., 2012).
FIGURE 2 | Antimicrobial and anticancer peptides (AMPs and ACPs)
are expected to show different modes of action. While for the BP100
AMP is possible to establish a correlation between the minimal inhibitory
concentration (MIC) and membrane charge (Alves et al., 2010) (A), for the
ACP SVS-1 membrane neutralization does not occur even after cell death
(B) (Gaspar et al., 2012; Sinthuvanich et al., 2012).
effects that ACPs exert upon cancer and healthy cells using
microscopy and fluorescence tools, it is common to search for
cell shrinkage or swelling, chromatin condensation, cytoplasmic
vacuoles or even membrane blebbing (Elmore, 2007). There are
many peptides capable of inducing these cellular changes. For
instance, the synthesized AMP epinecidin-1 selectively kills can-
cer cells at low concentration and studies of necrosis inhibition
test and real-time PCR indicate a membrane disruptive activ-
ity as well as an anti-necrosis effect by inhibition of necrosis
gene expression (Lin et al., 2009). Dermaseptin B2 is one other
example of a necrosis-inducing peptide. Increased lactate dehy-
drogenase (LDH) release, the positive staining with propidium
iodide (PI) as well as confocal microscopy studies points to a
necroticmechanismwhich in turnmight be induced after binding
and disruption of the plasma membrane (van Zoggel et al., 2012).
Also, induced apoptosis in several human cancer cell lines from
breast, uterine cervix, liver and prostate has been described as
the mode of action for different potential ACPs (Kim et al., 2003;
Feliu et al., 2010; Kawamoto et al., 2011; Ma et al., 2013). It is also
possible to attack metastatic tumor cells with peptide-induced
apoptosis (Yang et al., 2008) as well as induce apoptosis in the
tumor associated endothelial cells (Chen et al., 2001). As metas-
tases are responsible for increased therapy failure, peptides that
can specifically intervene in the process of metastases formation
stimulating neoplastic cell death are valuable resources in cancer
treatment. Chen et al. studied the effect of RGD-tachyplesin on
human prostate cancer and melanoma cells (Chen et al., 2001).
In this study, the natural tachyplesin was linked to a homing
domain which facilitates the AMP internalization into the cells
by the binding to integrins on tumor and endothelial cells (RGD
sequence). Results showed that the peptide inhibited not only the
growth of cancer cells both in vivo and in vitro with some degree
of selectivity, but also affected membrane function triggering
apoptosis (Chen et al., 2001).
Peptides that share both necrotic and apoptotic modes of
action have been also described. The conjugation of magainin
II (MG2) with the N-terminus of the cell penetrating peptide
penetratin (Antp) resulted in a fusion peptide, MG2A, active
against tumor cells with an IC50 in the micromolar range that
target chondroitin sulfate on the surface of tumor cells (Liu
et al., 2013). Tests involving apoptosis assessment by annexin
V and PI staining, fluorescence microscopy and FACS analysis
suggest necrotic cell death by membrane lysis while observ-
ing apoptotic cells. A different peptide also with dual mode
of action was described by Xu et al. (2013). A9K is a short
designed amphiphilic AMP which combines a short length with
other properties such as inherent surfactant-like and AMP activ-
ities, protease stability and absence of immunological responses.
Presents high selectivity for leukemia, uterine cervix and kidney
cancer cells killing cells by membrane disruption and apoptosis
(Xu et al., 2013).
Diversified modes of action and molecular targets
The modes of action for ACPs are not limited only to the dis-
ruption of the plasma and mitochondrial membranes with the
subsequent damages above-mentioned. Other mechanisms do
exist and have been described, while it is not unusual to find
peptides that combine more than one mechanism. These may
involve alternative pathways such as, mediated immunity (Wang
et al., 2009c), hormonal receptors (Leuschner and Hansel, 2005),
DNA synthesis inhibition (Ourth, 2011; Kuriyama et al., 2013)
and anti-angiogenic effects (Koskimaki et al., 2009) (Figure 3).
Indeed, one study showed that human neutrophil peptides HNP-
1 to 3 can exert several antitumor effects and that these might
occur by a variety of mechanisms (Wang et al., 2009c). HNP-1
to 3 belong to the α-defensin group and are potent AMP with
∼30 amino acid residues (Droin et al., 2009). Different studies
revealed that these peptides have potential as cancer prognostic
markers (Albrethsen et al., 2005, 2006; Droin et al., 2009), are
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FIGURE 3 | Anticancer peptides (ACPs) modes of action may include
disruption of plasma/ mitochondrial membranes (Sinthuvanich et al.,
2012), necrosis, apoptosis (van Zoggel et al., 2012; Xu et al., 2013),
mechanisms of mediated immunity (Wang et al., 2009c), membrane
receptors involvement (Leuschner and Hansel, 2005), inhibition of DNA
synthesis (Ourth, 2011) and anti-angiogenic effects (Koskimaki et al.,
2009). Different ACPs can act by more than one mechanism simultaneously
(Wang et al., 2009c; Xu et al., 2013).
active against a variety of healthy and malignant mammalian cells
(Nishimura et al., 2004; McKeown et al., 2006) and that they
are found in the tissue of epithelial tumors as well as they are
associated with tumor necrosis when expressed intratumorally
(Bateman et al., 1992; Muller et al., 2002). In this particular
study, Wang et al. showed that the expression of mature HNP-
1 in models of breast and colon tumors induced the recruitment
and activation of dendritic cells which led to an immune response
to the tumor from the host. HNP-1 intratumoral expression in
its mature form may inhibit and eradicate established tumors
(Wang et al., 2009c). Increased apoptosis and decreased angio-
genesis events are also reported with the antitumor effects. Other
studies reveal the potential in using peptides that target or mimic
hormonal receptors and hormonal-regulated genes for treating
cancer (Leuschner et al., 2003; Leuschner and Hansel, 2005;
Hansel et al., 2007; Kampa et al., 2011; Pelekanou et al., 2011;
Byrne et al., 2012; Gao et al., 2013). Leuschner et al. studied the
ability of a series of compounds formed by synthetic membrane-
disrupting peptides and a 15-amino acid residues segment of the
beta chain of chorionic gonadotropin in targeting cells expressing
luteinizing hormone/chorionic gonadotropin (LH/CG) receptors
(Leuschner and Hansel, 2005; Hansel et al., 2007). These formed
conjugates were able to destroy metastases and disseminated cells
derived from human prostate cancer xenografts in nude mice and
cells died by necrosis as revealed by histological examinations
(Leuschner and Hansel, 2005). These studies prove that the lytic
peptide conjugates might be useful for the inhibition of the devel-
opment of metastases after surgical removal of the primary tumor
(Hansel et al., 2007). In a different study, the ERα17p peptide
originated from part of the sequence of the estrogen receptor α
(ERα) was shown to interact with the polar part of the plasma cell
membrane, to penetrate it and induce cell membrane damage at
high concentration (Byrne et al., 2012).
Many other targets can be found for developing specific ACPs
and many proteins have been highlighted for this effect. Patra
et al. reported on the cell-permeable lipopeptide CR1166 that
inhibits the PDZ domain of the GIPC (GAIP-interacting protein,
C terminus) protein which is over expressed in breast and pan-
creas tumors (Patra et al., 2012). This inhibition interferes with
the protein-protein interactions disturbing the events involved
with GIPC activity and which in turn include tumor progression
(Patra et al., 2012). Effects were observed in vivo and in vitro and
account for decreased proliferation, cytotoxic effects and apop-
tosis on breast and pancreas cancer cells (Patra et al., 2012).
The heat shock protein 70 (HSP70) has been also described as
a potential protein target for treating neoplastic diseases (Rerole
et al., 2011), since its upregulation induces an increased tumori-
genicity of cancer cells in rodent models (Jaattela, 1995) and its
downregulation kills cancer cells or renders them susceptible to
apoptosis (Nylandsted et al., 2000). Molecules that inhibit matrix
metalloproteinases (MMPs) activity are also interesting potential
drugs (Destouches et al., 2012). MMPs are a family of membrane-
bound zinc endopeptidases that display an important activity
in what concerns remodeling of the extracellular matrix (ECM)
in processes as tumor development, angiogenesis and metastatic
progression (Coussens and Werb, 2002; Coussens et al., 2002;
Egeblad and Werb, 2002; Visse and Nagase, 2003; Jang et al.,
2011; Destouches et al., 2012). Many cancers express aberrant
MMPs quantities (Derrico et al., 1991; Davies et al., 1993) and
this fact can be used for creating strategies to block metastasis
process. For instance, buforin IIb, that displays activity against
60 human tumor cell lines (Lee et al., 2008), was fused with a
modified magainin sequence, a negative charge that would equi-
librate the overall positive charge of buforin II, generating the
MMIS:buforin IIb fusion peptide. Both peptide sequences were in
turn linked by an octapeptide, cleavable by theMMP-2 (gelatinase
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A) and MMP-9 (gelatinase B) enzymes which are over expressed
in tumor tissues, allowing the release of buforin IIb (Jang et al.,
2011). Cells expressing high amounts of MMPs such as mouse
melanoma, human fibrosarcoma and gliobastoma were sensitive
to this peptide. On the other hand, human uterine cervix cells
which deficiently express these MMPs were resistant, and the
fusion peptide anticancer activity was shown to be dependent on
enzymatic activity (Jang et al., 2011). Two final different exam-
ples concerns to tachyplesin and temporin-1CEa. Tachyplesin is a
peptide with 17 amino acid residues isolated from the horseshoe
crab, which revealed an antitumor activity connected to a bind-
ing to hyaluronan or related glycosaminoglicans on the surface of
cells and activation of the classic complement pathway leading to
the disruption of the plasma membrane (Chen et al., 2005). The
AMP temporin-1CEa causes breast cancer cell death by signifi-
cant membrane disruption, intracellular calcium release and ROS
over production (Wang et al., 2012, 2013a,b).
HEMATOLOGICAL TUMORS: LEUKEMIAS, MYELOMAS AND
LYMPHOMAS
Hematological malignancies consist in a broad spectrum of dis-
eases which comprise blood, bone marrow and lymph nodes
cancer and are classified as leukemia, myeloma and lymphoma,
respectively (Alvarez-Calderon et al., 2013). Estimates indicate a
3.4% of deaths caused by leukemia in 2008 (Ferlay et al., 2010). At
the present, hematologic cancer is treated with cytotoxic drugs,
radiation therapy or with bone marrow transplantation, which
is known to cause severe long-term effects on patients (Alvarez-
Calderon et al., 2013). As a complex group of diseases affecting
multiple cell types, the literature provides numerous examples of
peptides developed to target blood and bone marrow cells, many
of them designed also to be active against solid tumors (Table 3).
The multiple roles of the negatively charged cancer cell membrane
As above-mentioned, the existence of negatively charged
molecules on the cancer cell membrane might render cells sus-
ceptible to ACPs. Many peptides targeting non-solid tumors take
advantage from electrostatic attraction, such as the NK-2 pep-
tide derived from the cationic core region of NK-lysin from
porcine and T-cells. NK-2 has a positive net charge and selec-
tively kills cancer cells by a necrotic mechanism (Schroder-Borm
et al., 2005). This killing ability correlates with the exposure
of negatively charged PS on the surface of the cancer cell and
the intercalation of the peptide into PS-containing membranes,
being the leukemia cells with lower PS exposure the least sensitive
(Schroder-Borm et al., 2005). This study involved also cells from
solid tumors and Schroder-Borm et al. equally demonstrated the
importance of PS presence on the cell membrane for NK-2 activ-
ity toward neuroblastoma cells (Schroder-Borm et al., 2005). The
permeabilization of the plasma membrane due to pore forma-
tion by peptides was also demonstrated to occur by an increase in
the electrostatics interactions and the transmembrane potential
(Lemeshko, 2013). In this same study, the designed polycationic
peptides revealed a selective anticancer activity against cancer
human acute T cell leukemia which the authors attribute to higher
values of surface and membrane potential of tumor cells when
compared with normal cells (Lemeshko, 2013). Other different
examples regarding the importance of electrostatics interac-
tions in ACP—membrane interplay are patent on many studies
such as the ones with the already described AMP polybia-MPI
(Wang et al., 2009b) and with bovine lactoferricin 6 (LfcinB6)
(Richardson et al., 2009). The short α-helical peptide polybia-
MPI is selective toward leukemia cells probably due to the dif-
ferent amount of PS exposed in the cancer cell membrane (Wang
et al., 2009b). Cell proliferation, viability and cytotoxicity assays
revealed that polybia-MPI impaired the proliferation of sensitive
and MDR cells while inducing LDH activity. On the contrary,
the peptide showed lower effect on normal fibroblasts (Wang
et al., 2009b). The mechanism of action relied on the disrup-
tion of the plasma membrane by pore formation which was
shown by microscopy analyses. Upon contact with the negative
cell membrane, the peptide acquires helical conformation capable
of destroying the membrane (Wang et al., 2009b). Electrostatics
is thus the main force attraction and the hydrophobic interac-
tions allow the peptide insertion into the membrane. Leukemia
cells died by a necrosis effect, with cells swelling and bursting
(Wang et al., 2009b). Bovine lactoferricin (LfcinB) is a 25 amino
acid residues cationic AMP isolated from cows’ milk (Hoskin
and Ramamoorthy, 2008). This peptide presents an amphipathic
β-sheet configuration and displays anticancer activity against
leukemia cells and various other carcinomas (Mader et al., 2005)
being able to bind to GAGs of the cell membrane (Jenssen et al.,
2004). LfcinB is capable of inducing apoptosis by direct disrup-
tion of the mitochondrial membrane (Furlong et al., 2008), but
is also capable of lysing the membrane depending on the can-
cer cell type (Eliassen et al., 2006). LfcinB6 is the antimicrobial
core of LfcinB peptide with a +3 net charge conferred by the
three arginine residues in its sequence (Ueta et al., 2001). This
charge is expected to promote bacteria death (Ueta et al., 2001)
but it was insufficient for allowing the peptide binding and inter-
action with T cell leukemia membranes. Indeed, it was shown
that a net charge of at least +7 was required for a strong cyto-
toxic activity toward the tumor cells (Richardson et al., 2009).
On the other hand, the peptide showed cytotoxic activity when
delivered by fusogenic liposomes into the cytosolic compartment
of the same cells involving cathepsin B and caspase activities
(Richardson et al., 2009). On a different study, CB1a, a cecropin-
derived peptide, showed high cytotoxic activity against leukemia
and stomach carcinoma with low hemolysis (Wu et al., 2009). In
this case, the net positive charge of the peptide (+12) proved to be
important for its activity even though the exact mode of action
for this peptide is still poorly understood (Wu et al., 2009).
Even though peptides’ net positive charge is shown essen-
tially to have a promoting role in ACPs binding to the mem-
brane negative charge of cancer cells, the negative components
of the membrane might function also as inhibitors of the activ-
ity. Indeed, LfcinB and KW5, a derived peptide from LfcinB
with 21 amino acid residues designed to adopt an idealized
amphipathic α-helical structure, were shown to have decreased
effect on lymphoma cells expressing heparan sulfate (HS) on the
cell surface (Fadnes et al., 2009). It was proposed that the HS
at the surface of cells sequester the peptide molecules leading
them away from the membrane bilayer and thus poorly dif-
ferentiated tumors with low expression of cell surface HS are
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Table 3 | Peptides and their respective oncolytic properties against hematological tumors.
Peptide Cancer cell Experimental
test
Selectivity Anticancer activity References
NK-2 Human chronic myelogenous
leukemia, histiocytic lymphoma,
acute T cell leukemia, acute
lymphoblastic leukemia,
neuroblastoma, colorectal
adenocarcinoma
ICL Yes Necrotic death after
peptide intercalation
into PS-containing
membranes
Schroder-Borm et al., 2005
Polycationic peptides Human acute T cell leukemia ICL Yes Plasma membrane
permeabilization by
pore formation
Lemeshko, 2013
Polybia-MPI Human chronic myelogenous
leukemia, promyelocytic leukemia,
mouse lymphocytic leukemia
ICL Yes Disruption of the
plasma membrane
by pore formation
Wang et al., 2009b
Bovine Lactoferricin
(LfcinB)
Human acute lymphoblastic T
leukemia, acute T cell leukemia
ICL Yes Apoptosis by direct
disruption of the
mitochondrial
membrane
Furlong et al., 2008
Bovine Lactoferricin
B6 (LfcinB6)
Human acute T cell leukemia, acute
lymphoblastic T leukemia
ICL Yes Intracellular
cytotoxicity by
cathepsin B and
caspase activation
Richardson et al., 2009
Cecropin CB1a Human acute lymphoblastic
T-leukemia cells, lung carcinoma,
stomach carcinoma
ICL Yes Unclear mode of
action
Wu et al., 2009
SK84 Human leukemia, liver and breast ICL Membrane
disruption
Lu and Chen, 2010
Magainin analogues Human acute T and B cell leukemia,
human chronic myelogenous
leukemia, human histiocytic/Burkitt
lymphoma, Ape T cell leukemia,
human breast, prostate and
neuroepithelioma
ICL Yes Membrane Lysis Cruciani et al., 1991
Cecropin CB1 Human chronic myelogenous
leukemia, acute T cell leukemia,
acute lymphoblastic T-leukemia
ICL Nd Membrane Lysis Srisailam et al., 2000
Pep 2 and Pep3 Human chronic myelogenous
leukemia, acute lymphoblastic
T-leukemia cells
ICL Yes Apoptosis of cancer
cells through
activation of
caspases -3 and -9
Edison et al., 2012
BIM SAHBA Human histiocytic lymphoma,
chronic myelogenous leukemia,
acute myeloid leukemia
CT Yes Apoptotic resistance
overcoming
Labelle et al., 2012
Nd, not determined; ICL, immortal cancer-cell lineage; CT, clinical trial.
more susceptible to peptides’ activity (Fadnes et al., 2009). Apart
from this inhibitory effect of the negatively charged molecules
expressed on cancer cell surface, it is also possible to find peptides
that seem insensitive to differences in the membrane charge, like
SK84 (Lu and Chen, 2010). SK84 is a glycine-rich non-cationic
AMP isolated from Drosophila virilis which membrane disrup-
tion activity of leukemia cells was evidenced by SEM (Lu and
Chen, 2010). This disruption might be consequence of the per-
turbation of the membrane not due to electrostatic forces but
by the formation of an elastic structure via the peptide flexible
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N-terminal glycine-rich domains (Lu and Chen, 2010). The SK84
peptide, with this unusual mode of action, is toxic to leukemia,
liver and breast cancer cells, while remains non-toxic to mouse
and human erythrocytes (Lu and Chen, 2010).
Peptide activity on non-solid tumors
Magainins are naturally occurring peptides isolated from the
skin of Xenopus laevis that present antibiotic activity toward dif-
ferent microorganisms (Cruciani et al., 1991). These molecules
are α-helical peptides with separate cationic and hydropho-
bic faces comprising 21–27 amino acid residues (Hoskin and
Ramamoorthy, 2008). Cruciani et al. showed that nine synthetic
magainin peptide analogs lyse in a rapid and irreversible way sev-
eral hematopoietic tumors with a cytotoxicity comparable to their
antibacterial activity and with relatively non-toxicity to differen-
tiated normal cells, peripheral blood lymphocytes (PBLs), and
polymorphonuclear lymphocytes (PMNs) (Cruciani et al., 1991).
The study revealed that all the tested hematopoietic cell lines
were sensible to the peptides derivatives with varying degrees of
cytolytic activity withinminutes. It also showed that themagainin
derivatives were selective toward the tumor cells at concentrations
5–10 times greater than those required for antibiotic effects but
10–20 times less than those which are toxic to normally differ-
entiated cells (Cruciani et al., 1991). In agreement to magainins
described mode of action, the permeability of tumor cell mem-
branes was affected by α-helical channel formation on the cell
membrane while non-cytolytic concentrations of these peptides
were not sufficient to form selective α-helical ion channels capable
of compromising cell viability (Cruciani et al., 1991).
Also α-helical peptides, cecropin derivatives have been stud-
ied as potential alternatives for targeting leukemia cells (Srisailam
et al., 2000; Wu et al., 2009). In a study conducted using a cus-
tom AMP, cecropin B1 (CB1), researchers point out that parallel
to the importance given to peptide structure, the orientation of
the peptide after approaching the surface of the polar lipid heads
conditions peptides’ activity (Srisailam et al., 2000). CB1 activity
was compared with two amphipatic α-helical segments derived
from the natural cecropin B (CB) and no selective activity for
CB1 was described while the differences reported for the IC50 val-
ues for different leukemia cell lines have been attributed to the
heterogeneity regarding the different tested cells. Thus, adding to
the structure and helix stability and to peptide self-orientation,
the peptide flexibility appears to be a key factor for the efficient
insertion on the membrane in the first events of membrane lysis
(Srisailam et al., 2000).
Apart from LfcinB, other peptides have been recently described
as apoptosis inducers in leukemia cells (Edison et al., 2012;
Labelle et al., 2012). Pep2 and Pep3 are short synthetic peptides
derived from the C-terminus of the proapoptotic mitochon-
drial protein ARTS and were shown to efficiently kill cells from
human leukemia (Edison et al., 2012). Also, a stapled peptide
combining the Bcl-2 interacting mediator of cell death (BIM)
with stabilized α-helix of Bcl-2 domain (SAHBs) named BIM
SAHBA was recently developed for targeting the Bcl-2 path-
way (Labelle et al., 2012). This peptide disables survival pro-
teins and activates the Bcl-2 family proteins resulting in cancer
cell death by overcoming the apoptotic resistance expressed in
hematological cancers (Labelle et al., 2012). Experiments showed
that the peptide was able to suppress the growth of drug-resistant
leukemia tumors in mice and also showed a synergistic anti-
cancer effect when administered with other drugs (Labelle et al.,
2012).
PERSPECTIVES AND OPEN QUESTIONS ON ANTICANCER
PEPTIDES DESIGN AND DEVELOPMENT
The use of peptides in clinical treatments has many advantages
as well as drawbacks. The challenge in ACP designing lies on the
improvements of their delivery to the tumors while maintaining
a low profile of toxic effects. The low selectivity of some of the
ACPs molecules, the high cost of production in large scale, and
their low resistance to proteolytic cleavage (Hu et al., 2011) are
some of themain reasons why peptides have been retained in drug
development pipelines. There are also some concerns related to
the use of AMPs whose sequences are close to human and nat-
ural AMPs due to a possible compromise of the human natural
defense and consequently threat to public health (Chen et al.,
2012). On a positive view, since ACPs are not directed to a spe-
cific extracellular or intracellular receptor, some mechanisms of
resistance can be impaired (Giuliani et al., 2007; Torfoss et al.,
2012b) and actually some AMPs have shown cytotoxic activity
against MDR cancer cells (Johnstone et al., 2000). The success for
obtaining an optimal ACP relies then on the manipulation of its
sequence, net charge, secondary structure, oligomerization abil-
ity, amphipathicity and hydrophobicity while maintaining high
serum stability. The result should be a balanced equilibrium
between these characteristics. Although there are no defined rules
for designing ACPs, some facts established through structure-
activity studies might help in elucidating the lack of selectivity
for some peptides and potentiate drug development strategies.
During the rational drug designing process differences in the pat-
tern expression of surface molecules or in membrane fluidity
between malignant cells types which may dictate the preference
of the peptides for certain cancer cells in detriment of others
(Fadnes et al., 2011) should not be neglected. Peptides’ ability
in crossing the cell membrane to reach intracellular targets is a
major requirement for developing an anticancer agent. Peptides’
structure might condition its internalization as well as contribute
exponentially to the productions cost. Identifying the amino acid
sequence in the peptides full sequence which might be responsi-
ble for the anticancer activity will certainly help reducing the high
cost production by allowing the synthesis of shorter fragments
that retain full biological activity. Many pharmacological param-
eters will be improved with this process, such as bioavailability
and stability, and also immunogenicity is expected to decrease
(Fadnes et al., 2011). It might also be expected that the shorter
peptides are more efficient in reaching the membrane phospho-
lipid bilayer with a concomitant increase of peptides’ cytotoxicity
(Fadnes et al., 2011). One clear and recent example reports to
FK-16 peptide, a fragment of LL-37 which is the only peptide
from the cathelicidin familiy found in humans (Ren et al., 2013).
This shorter fragment showed an improved anticancer activity
when compared to the original sequence and was described as
capable to kill colon cancer cells by autophagic cell death, an
additional cell death pathway, while reducing cost production
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(Ren et al., 2013). It has been shown that arginine residues in
cationic AMPs interact strongly with zwitterionic phospholipids
which may result in toxicity events (Yang et al., 2003; Giuliani
et al., 2007). It is therefore expected that other cationic residues
might be used when constructing an ACP, such as lysine, to
direct the peptide binding toward the negatively charged cells and
simultaneously avoid hemolytic events. Serum stability might be
improved by the incorporation of D-amino acids on the peptide
sequence (Riedl et al., 2011b) and by cyclization of the structures
(Torfoss et al., 2012b). The incorporation of lipophilic β2, 2 amino
acids building blocks into heptapeptides resulted in a potent anti-
cancer activity toward human and murine lymphoma cells, as
well as high proteolytic stability and low toxicity against non-
tumor cells (Torfoss et al., 2012a,b). The authors of this study
state that the incorporation of the disubstituted β2, 2 amino acids
in an α-helical peptide added an extra methylene group to the
structure which in combination with two bulky lipophilic sub-
stituents, increased stability to protein degradation. Indeed, the
central β2, 2 amino acid is flanked by two tryptophan residues to
increase bulkiness and forming a lipophilic sequence where lysine
cationic residues, are located at the N- and C-terminals (Torfoss
et al., 2012a). The cyclization of these peptides resulted in struc-
tures with increased rigidity, amphipathicity and with changes in
the secondary structure conformation which lead to an improve-
ment of the anticancer potency against human lymphoma cells
(Torfoss et al., 2012b).
The hydrophobicity of the peptides is also an important prop-
erty when considered the hydrophobic environment that char-
acterizes the cell membrane and it can be easily modulated in
order to increase anticancer activity (Huang et al., 2011). In one
recent study, the authors proved that manipulating the hydropho-
bicity of a 26-amino acid residues amphipathic peptide, V13K,
by changing between alanine—leucine residues, it was possible
to increase peptide activity against cancer cells, having human
cervix cells shown high sensitivity, and thus showed a correla-
tion between hydrophobicity—anticancer activity (Huang et al.,
2011). Increasing hydrophobicity on the nonpolar face of the
peptides enhanced their helical structure which in combination
with the hydrophobicity resulted in stronger self-association and
anticancer activity (Huang et al., 2011). In turn, helical structure
acquisition can be controlled by D-amino acid substitution which
may also modulate peptide specificity (Huang et al., 2012). The
same study allowed the simultaneous observation of an increased
hemolytic activity with the increase of the hydrophobicity of the
peptides revealing a low degree of specificity. In 2013, a dif-
ferent study supported the same correlation between increasing
hydrophobicity and anticancer and hemolytic activities (Yang
et al., 2013). The authors suggest that high cationicity for enhanc-
ing neoplastic cell specificity and controlled hydrophobicity for
equilibrating the hemolysis effect might be a suitable strategy for
drug design (Yang et al., 2013).
Tumorigenesis is a multistep process where many factors inter-
vene for the tumor growth and progression as well as in the
metastatic and angiogenic events. For an effective targeting of
each step, new therapeutic agents with the ability to kill slow-
growing and drug resistant cancer cells, despite their proliferative
capacity, are needed. The design of an oncolytic peptide with opti-
mized properties and with high impact on the area of cancer treat-
ment requires obtaining precise information concerning peptides’
activity on the cell membranes at high resolution and detail. Once
this goal is achieved, and combined with the advance knowledge
on cancer biology, the optimized peptide may prove to be eco-
nomically and therapeutically viable and a valuable alternative to
current chemotherapeutics. These new chemotherapeutic drugs
may synergize with the existing agents to restrict tumor activity
and it is unlikely that they elicit multidrug resistance mechanisms
and increase side-effects on healthy tissues and organs.
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